Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RARE

RARE - Ultragenyx Pharmaceutical Inc Stock Price, Fair Value and News

$24.44-0.18 (-0.73%)
Market Closed

40/100

RARE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

40/100

RARE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$20.92

Target 3M

$23.34

Target 6M

$22.52

RARE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RARE Price Action

Last 7 days

7.4%

Last 30 days

23.9%

Last 90 days

-30.5%

Trailing 12 Months

-42.5%

RARE RSI Chart

RARE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RARE Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-4.07

Price/Sales (Trailing)

3.74

EV/EBITDA

-3.98

Price/Free Cashflow

-5.22

RARE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$20.92

Target 3M

$23.34

Target 6M

$22.52

RARE Fundamentals

RARE Revenue

Revenue (TTM)

630.6M

Rev. Growth (Yr)

14.65%

Rev. Growth (Qtr)

-3.94%

RARE Earnings

Earnings (TTM)

-579.8M

Earnings Growth (Yr)

-35.12%

Earnings Growth (Qtr)

-56.95%

RARE Profitability

Operating Margin

84.69%

EBT Margin

-91.46%

Return on Equity

-6.3K%

Return on Assets

-48.71%

Free Cashflow Yield

-19.14%

RARE Investor Care

Shares Dilution (1Y)

4.48%

Diluted EPS (TTM)

-5.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025590.7M610.2M630.6M0
2024442.6M481.3M522.7M560.2M
2023383.9M402.9M410.2M434.2M
2022331.9M334.3M343.4M363.3M
2021334.1M359.4M359.6M351.4M
2020121.9M159.4M215.1M271.0M
201959.0M70.3M84.4M103.7M
201813.3M26.1M37.6M51.5M
201700331.0K2.7M
20160322.0K370.0K282.0K
20140331.0K00
20130000
Get all data in R, Python etc through our Historical Stock Data APIs

About Ultragenyx Pharmaceutical Inc

RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
 CEO
 WEBSITEultragenyx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES1311

Ultragenyx Pharmaceutical Inc Frequently Asked Questions

RARE is the stock ticker symbol of Ultragenyx Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Ultragenyx Pharmaceutical Inc is 2.36 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RARE's fair value in chart for subscribers.

The fair value guage provides a quick view whether RARE is over valued or under valued. Whether Ultragenyx Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact Ultragenyx Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RARE.

As of Wed Jan 28 2026, RARE's PE ratio (Price to Earnings) is -4.07 and Price to Sales (PS) ratio is 3.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RARE PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Ultragenyx Pharmaceutical Inc has provided -0.08 (multiply by 100 for percentage) rate of return.